Abstract: Bemcentinib (also known as BGB324 or R428) is a first-in-class, highly selective, orally bioavailable small-molecule inhibitor targeting the AXL receptor tyrosine kinase. AXL signaling is a critical driver of tumor progression, epithelial-mesenchymal transition (EMT), immune evasion, and therapeutic resistance across multiple malignancies. In the context of Acute Myeloid Leukemia (AML), bemcentinib has demonstrated significant clinical potential, earning FDA Fast Track designation for elderly patients with relapsed AML. It exerts its antitumor effects by binding to the ATP-binding pocket of AXL, thereby blocking autophosphorylation and downstream oncogenic signaling cascades. Furthermore, bemcentinib remodels the tumor microenvironment by enhancing dendritic cell activity and reducing immunosuppressive cells. While its safety profile is generally manageable, challenges such as acquired resistance through compensatory signaling and specific toxicities necessitate ongoing research into biomarker-driven patient selection and rational combination therapies.
1. Introduction
Acute Myeloid Leukemia (AML) and other aggressive malignancies frequently exploit cellular plasticity and adaptive signaling to evade therapeutic interventions. A key regulator of this process is the mesenchymal-epithelial transition/plasticity (MET/EMP) axis, which drives tumor development, progression, and resistance [1]. Central to this axis is AXL, a receptor tyrosine kinase belonging to the TAM (TYRO3, AXL, MER) family. AXL is strongly associated with tumor survival, metastasis, therapy resistance, and immune evasion [1] [2].
Bemcentinib (BGB324, R428), developed by BerGenBio ASA, is a highly selective, orally bioavailable small-molecule inhibitor of AXL [1]. As a first-in-class AXL inhibitor, bemcentinib exemplifies precision oncology by targeting tumor-intrinsic AXL signaling while simultaneously modulating the immune microenvironment [1]. It is currently under extensive clinical development for various cancers, including AML, where it has been granted FDA Fast Track designation for elderly patients with relapsed disease [1].
2. Pharmacological Activity
Bemcentinib demonstrates potent AXL inhibition and antitumor activity both as a monotherapy and in combination regimens [1]. In the clinical landscape of AML and myelodysplastic syndromes (MDS), bemcentinib is being actively evaluated. Notable clinical trials include the Phase II BERGAMO trial, which investigates the efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or AML who have failed hypomethylating agents [1]. Additionally, the Phase Ib/II BGBC003 trial has evaluated bemcentinib as a monotherapy and in combination with low-dose cytarabine or decitabine in patients with relapsed/refractory AML and MDS, particularly those unfit for intensive chemotherapy [1].
Pharmacokinetically, bemcentinib is administered orally once daily. It exhibits favorable properties characterized by rapid absorption and high bioavailability. Steady-state plasma concentrations are achieved within days, ensuring sustained AXL inhibition. The drug undergoes hepatic metabolism primarily via the CYP3A4 enzyme, which necessitates careful monitoring for potential drug-drug interactions [1]. Target engagement has been successfully confirmed in patient biopsies through the observation of reduced phosphorylated AXL levels [1].
3. Molecular Mechanism of Action
Bemcentinib functions by selectively binding to the ATP-binding pocket of the AXL receptor tyrosine kinase. This binding blocks AXL autophosphorylation and subsequently halts downstream signaling cascades, including the PI3K/AKT, MAPK/ERK, NF-κB, and STAT3 pathways, which are normally activated by the AXL ligand GAS6 [1]. By inhibiting these pathways, bemcentinib suppresses tumor proliferation, invasion, and metastasis, and promotes the reversal of epithelial-mesenchymal transition (EMT) [1].
At the cellular level, AXL inhibition by bemcentinib induces DNA damage and replication stress, leading to G2/M cell cycle arrest and apoptosis. It also down-regulates DNA repair genes, which can sensitize cancer cells to other targeted therapies [2]. Beyond its direct effects on tumor cells, bemcentinib actively remodels the tumor microenvironment (TME). It enhances the activity of dendritic cells, reduces the presence of immunosuppressive regulatory T cells (Tregs), and decreases PD-L1 expression, thereby improving the tumor's responsiveness to immune checkpoint blockade [1] [2].
4. Structure-Activity Relationship (SAR)
While comprehensive structural modification data is not detailed in the provided literature, the primary structure-activity relationship of bemcentinib hinges on its ability to act as an ATP-competitive inhibitor. Bemcentinib (R428) achieves its high selectivity and potency by specifically targeting and binding to the ATP-binding pocket of the AXL kinase domain [1]. This precise interaction is responsible for its ability to block the autophosphorylation of AXL without broadly inhibiting other off-target kinases, distinguishing it as a highly selective agent among TAM family inhibitors [1].
5. Current Limitations
Despite its therapeutic promise, the clinical application of bemcentinib faces several limitations. Acquired resistance remains a significant challenge; tumors can bypass AXL inhibition through compensatory signaling via parallel pathways (such as c-MET, HER3, or EGFR) or by acquiring mutations within the AXL kinase domain [1] [2].
Additionally, bemcentinib is associated with a specific toxicity profile. While generally manageable, common adverse effects include fatigue, nausea, diarrhea, anemia, thrombocytopenia, QTc prolongation, and mild transaminase (ALT/AST) elevations [1]. Less frequent but notable toxicities require vigilant monitoring, including hepatotoxicity (Grade 3 ALT/AST elevations have been reported) and pneumonitis [1]. Rare adverse events include rash, hypersensitivity, and medication-related osteonecrosis of the jaw (MRONJ) [1]. Furthermore, its metabolism via CYP3A4 requires strict monitoring to prevent adverse drug-drug interactions [1].
6. Future Perspectives
The future development of bemcentinib in AML and other malignancies relies heavily on refining combination strategies and advancing personalized medicine approaches. Ongoing studies are focused on overcoming resistance by combining bemcentinib with other targeted agents, chemotherapies (like cytarabine or decitabine), and immune checkpoint inhibitors to maximize the therapeutic window [1] [2].
A critical future direction is the establishment of robust predictive biomarkers to guide patient selection. Candidates for biomarker-driven stratification include AXL expression levels (measured via immunohistochemistry), circulating GAS6 levels, mesenchymal gene signatures, and circulating tumor DNA (ctDNA) [1]. By integrating dynamic biomarker assessments and rational combination regimens, bemcentinib has the potential to overcome adaptive resistance and significantly improve clinical outcomes for patients with aggressive and refractory cancers like AML [1].
